[EN] METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR UNE CANCÉROTHÉRAPIE SÉLECTIVE ET CIBLÉE
申请人:UNIV TEXAS
公开号:WO2015035051A1
公开(公告)日:2015-03-12
Provided herein are methods and compositions for selective and targeted cancer therapy, in particular certain benzothiophenes, benzothiazoles, oxalamides, N-acyl ureas and chromones, and their use in selectively treating certain adenocarcinomas. In some embodiments, the selective toxicity of the compounds may be mediated through SCD1 and/or CYP450 such as CYP4F11.
Synthesis, in vitro and computational studies of protein tyrosine phosphatase 1B inhibition of a small library of 2-arylsulfonylaminobenzothiazoles with antihyperglycemic activity
interactions between the nitrogroup in both compounds and the catalytic amino acid residues Arg 221 and Ser 216. Both compounds were evaluated for their in vivo antihyperglycemic activity in a type 2 diabetes mellitus rat model, showing significant lowering of plasma glucose concentration, during the 7 h post-intragastric administration.
Methods and Compositions for Selective and Targeted Cancer Therapy
申请人:BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
公开号:US20160200695A1
公开(公告)日:2016-07-14
Provided herein are methods and compositions for selective and targeted cancer therapy, in particular certain benzothiophenes, benzothiazoles, oxalamides, N-acyl ureas and chromones, and their use in selectively treating certain adenocarcinomas. In some embodiments, the selective toxicity of the compounds may be mediated through SCD1 and/or CYP450 such as CYP4F11.
Antidiabetic activity of N-(6-substituted-1,3-benzothiazol-2-yl)benzenesulfonamides
作者:Hermenegilda Moreno-Díaz、Rafael Villalobos-Molina、Rolffy Ortiz-Andrade、Daniel Díaz-Coutiño、Jose Luis Medina-Franco、Scott P. Webster、Margaret Binnie、Samuel Estrada-Soto、Maximiliano Ibarra-Barajas、Ismael León-Rivera、Gabriel Navarrete-Vázquez
DOI:10.1016/j.bmcl.2008.03.086
日期:2008.5
N-(6-Substituted-1,3-benzothiazol-2-yl)benzenesulfonamide derivatives 1-8 were synthesized and evaluated for their in vivo antidiabetic activity in a non-insulin-dependent diabetes mellitus rat model. Several compounds synthesized showed significant lowering of plasma glucose level in this model. As a possible mode of action, the compounds were in vitro evaluated as 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) inhibitors. The most active compounds (3 and 4) were docked into the crystal structure of 11 beta-HSD1. Docking results indicate potential hydrogen bond interactions with catalytic amino acid residues. (c) 2008 Elsevier Ltd. All rights reserved.